|Auxilium Pharmaceuticals Inc.|
640 Lee Road
United States - Map
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, together with its subsidiaries, develops and markets pharmaceutical products for urology and sexual health worldwide. The company markets Testim, a testosterone gel for the topical treatment of hypogonadism; TESTOPEL, an implantable TRT product; Edex, a injectable drug for erectile dysfunction (ED); Osbon ErecAid, a device for treating ED; STENDRA, a line oral therapy for ED; Striant, a buccal system for testosterone delivery; and XIAFLEX for the treatment of Dupuytren's contracture in adults with a palpable cord, as well as for the treatment of Peyronies. It also markets Theo-24 for the treatment of COPD and asthma; and Semprex-D for the treatment of seasonal allergic rhinitis. In addition, the company is developing XIAFLEX, which is in Phase IIb clinical trial for the treatment of adhesive capsulitis, as well as in Phase IIa clinical trial for the treatment of edematous fibrosclerotic panniculopathy. Further, it is developing a high concentration testosterone gel product. The company sells its products to wholesale drug distributors, specialty pharmacies, specialty distributors, and chain drug stores. It has a development and license agreement with BioSpecifics Technologies Corp.; development, commercialization, and supply agreement with Pfizer, Inc.; collaboration agreement with the Swedish Orphan Biovitrum AB; development, commercialization, and supply agreement with Asahi Kasei Pharma Corporation; and collaboration agreement with Actelion Pharmaceuticals Ltd. The company was founded in 1999 and is headquartered in Chesterbrook, Pennsylvania.
|Auxilium Pharmaceuticals Inc.’s ISS Governance QuickScore as of Apr 1, 2014 is 4. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 4; Compensation: 5.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Adrian Adams ,
Chief Exec. Officer, Pres and Director
|Mr. James E. Fickenscher ,
Chief Financial Officer and Principal Accounting Officer
|Mr. Andrew I. Koven ,
Chief Admin. Officer, Exec. VP, Gen. Counsel and Sec.
|Mr. Alan J. Wills ,
Exec. VP of Corp. Devel.
|Dr. James Patrick Tursi M.D.,
Chief Medical Officer
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|